Clinical and Experimental Vaccine Research

  • 제11권2호
  • /
  • Pages.184-192
  • /
  • 2022
  • /
  • 2287-3651(pISSN)
  • /
  • 2287-366X(eISSN)
대한백신학회 (The Korean Vaccine Society)
권호 표지
DOI QR코드

DOI QR Code

Nasal vaccine as a booster shot: a viable solution to restrict pandemic?

  • Sarasa Meenakshi (Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER)) ;
  • V .Udaya Kumar (Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER)) ;
  • Sameer Dhingra (Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER)) ;
  • Krishna Murti (Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER))
  • 투고 : 2022.02.27
  • 심사 : 2022.05.03
  • 발행 : 2022.05.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The coronavirus disease 2019 (COVID-19) pandemic revolutionized the vaccine market and initiated the momentum for alternative routes of administration for vaccines. The intranasal route of immunization is one such possibility that appears to be the most promising since it has some significant advantages, particularly in the prevention of respiratory infection. To analyze and summarize the role of nasal vaccines over conventional vaccines during COVID-19 and the need for the nasal vaccine as a booster shot. In this narrative review, the required data was retrieved using keywords "COVID-19," "Intranasal," "Immunity," "Nasal spray," and "Mucosal" in databases including PubMed, Scopus, Embase, Science Direct, and Web of Sciences. The results of the study showed that the nasal vaccines were both effective and protective according to the current researches approaching during the COVID-19 period and the preclinical and clinical phase trials prove the intranasal vaccination elicits more robust and cross-protective immunity than conventional vaccines. In this narrative review article, mechanisms across the nasal mucosa will be briefly presented and the current status of nasal vaccines during the COVID-19 pandemic is summarized, and advantages over traditional vaccines are provided. Furthermore, after exploring the primary benefits and kinetics of nasal vaccine, the potential for consideration of nasal vaccine as a booster dose is also discussed.

키워드

참고문헌

  1. Czochor J, Turchick A. Introduction: vaccines. Yale J Biol Med 2014;87:401-2.
  2. Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M. Understanding modern-day vaccines: what you need to know. Ann Med 2018;50:110-20.
  3. Lahariya C. Vaccine epidemiology: a review. J Family Med Prim Care 2016;5:7-15.
  4. Djupesland PG. Nasal delivery of vaccines: EPC (2003 Jan 29). Munich, European Patent Convention; 2003.
  5. Birkhoff M, Leitz M, Marx D. Advantages of intranasal vaccination and considerations on device selection. Indian J Pharm Sci 2009;71:729-31.
  6. Giudice EL, Campbell JD. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006;58:68-89.
  7. Yusuf H, Kett V. Current prospects and future challenges for nasal vaccine delivery. Hum Vaccin Immunother 2017;13:34-45.
  8. Ramvikas M, Arumugam M, Chakrabarti SR, Jaganathan KS. Nasal vaccine delivery. In: Skwarczynski M, Toth I, editors. Micro and nanotechnology in vaccine development. Oxford: William Andrew Publishing; 2017. p. 279-301.
  9. Grassin-Delyle S, Buenestado A, Naline E, et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther 2012;134:366-79.
  10. Illum L, Davis SS. Nasal vaccination: a non-invasive vaccine delivery method that holds great promise for the future. Adv Drug Deliv Rev 2001;51:1-3.
  11. Jabbal-Gill I. Nasal vaccine innovation. J Drug Target 2010;18:771-86.
  12. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003;21:1776-9.
  13. Chen JR, Liu YM, Tseng YC, Ma C. Better influenza vaccines: an industry perspective. J Biomed Sci 2020;27:33.
  14. Gasparini R, Amicizia D, Lai PL, Panatto D. Influenza vaccination: from epidemiological aspects and advances in research to dissent and vaccination policies. J Prev Med Hyg 2016;57:E1-4.
  15. Mohn KG, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated influenza vaccination. Hum Vaccin Immunother 2018;14:571-8.
  16. Wong SS, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev 2013;26:476-92.
  17. Crepey P, Redondo E, Diez-Domingo J, et al. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain. PLoS One 2020;15:e0233526.
  18. Shasha D, Valinsky L, Hershkowitz Sikron F, et al. Quadrivalent versus trivalent influenza vaccine: clinical outcomes in two influenza seasons, historical cohort study. Clin Microbiol Infect 2020;26:101-6.
  19. Ortiz de Lejarazu R, Diez Domingo J, Gil de Miguel A, et al. Description of influenza B in seasonal epidemics in Spain. Rev Esp Quimioter 2018;31:511-9.
  20. Tanner AR, Dorey RB, Brendish NJ, Clark TW. Influenza vaccination: protecting the most vulnerable. Eur Respir Rev 2021;30:200258.
  21. Rudenko L, Kiseleva I, Krutikova E, et al. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: protective vaccine efficacy in the ferret model. PLoS One 2018;13:e0208028.
  22. Hoft DF, Lottenbach KR, Blazevic A, et al. Comparisons of the humoral and cellular immune responses induced by live attenuated influenza vaccine and inactivated influenza vaccine in adults. Clin Vaccine Immunol 2017;24:e00414-16.
  23. de Swart RL, de Vries RD, Rennick LJ, et al. Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection. NPJ Vaccines 2017;2:22.
  24. Low N, Kraemer S, Schneider M, Restrepo AM. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 2008;26:383-98.
  25. Vila A, Sanchez A, Janes K, et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 2004;57:123-31.
  26. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoidhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005;57:1640-65.
  27. Wang S, Liu H, Zhang X, Qian F. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell 2015;6:480-503.
  28. Ahmed S, Sileno AP, deMeireles JC, et al. Effects of pH and dose on nasal absorption of scopolamine hydrobromide in human subjects. Pharm Res 2000;17:974-7.
  29. Davis SS. Nasal vaccines. Adv Drug Deliv Rev 2001;51:21-42.
  30. Slutter B, Hagenaars N, Jiskoot W. Rational design of nasal vaccines. J Drug Target 2008;16:1-17.
  31. Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003;42:1107-28.
  32. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001;53:3-21.
  33. Illum L. Nasal drug delivery: possibilities, problems and solutions. J Control Release 2003;87:187-98.
  34. Scherliess R. Nasal formulations for drug administration and characterization of nasal preparations in drug delivery. Ther Deliv 2020;11:183-91.
  35. Smith A, Perelman M, Hinchcliffe M. Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines. Hum Vaccin Immunother 2014;10:797-807.
  36. Ozsoy Y, Gungor S, Cevher E. Nasal delivery of high molecular weight drugs. Molecules 2009;14:3754-79.
  37. Djupesland PG, Skretting A. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv 2012;25:280-9.
  38. Koping-Hoggard M, Sanchez A, Alonso MJ. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines 2005;4:185-96.
  39. Guo C. Oxford-AstraZeneca COVID-19 vaccine (AZD1222), an approved, non-replicating chimpanzee adenovirus-vectored vaccine for the COVID-19 pandemic. J Appl Med Sci 2021;10:1-12.
  40. Zaman M, Chandrudu S, Toth I. Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res 2013;3:100-9.
  41. Shah SS, Patel CM, Patel DH, Vadgama PH, Patel M, Trivedi R. A Review on modern use of intranasal vaccination in the treatment of SARS-COV-2. J Drug Deliv Ther 2021;11(4-S):263-70.
  42. Azegami T, Yuki Y, Kiyono H. Challenges in mucosal vaccines for the control of infectious diseases. Int Immunol 2014;26:517-28.
  43. Wu HY, Nguyen HH, Russell MW. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scand J Immunol 1997;46:506-13.
  44. Fujimura Y. Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch 2000;436:560-6.
  45. Johansen FE, Kaetzel CS. Regulation of the polymeric immunoglobulin receptor and IgA transport: new advances in environmental factors that stimulate pIgR expression and its role in mucosal immunity. Mucosal Immunol 2011;4:598-602.
  46. Ogasawara N, Kojima T, Go M, et al. Epithelial barrier and antigen uptake in lymphoepithelium of human adenoids. Acta Otolaryngol 2011;131:116-23.
  47. Hung IFN, Poland GA. Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet 2021;397:854-5.
  48. Bar-On YM, Goldberg Y, Mandel M, et al. Protection across age groups of BNT162b2 vaccine booster against COVID-19. medRxiv [Preprint] 2021 Jan 1 [Epub]. https://doi.org/10.1101/2021.10.07.21264626.
  49. Mahase E. COVID-19: two vaccine doses are crucial for protection against delta, study finds. BMJ 2021;374:n2029.
  50. Liu X, Shaw RH, Stuart AS, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 2021;398:856-69.
  51. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282:137-44.